12 Health Care Stocks Moving In Friday's After-Market Session

Benzinga · 04/25 21:06
Gainers
- Molecular Partners (NASDAQ:MOLN) shares moved upwards by 24.8% to $5.24 during Friday's after-market session. The company's market cap stands at $193.2 million.
- VolitionRX (AMEX:VNRX) shares increased by 12.93% to $0.55. The market value of their outstanding shares is at $54.0 million.
- Kairos Pharma (AMEX:KAPA) shares moved upwards by 9.91% to $0.95. The market value of their outstanding shares is at $15.9 million.
- Concord Medical Services (NYSE:CCM) shares increased by 8.51% to $5.77. The company's market cap stands at $250.5 million.
- Intensity Therapeutics (NASDAQ:INTS) shares increased by 6.91% to $0.6. The company's market cap stands at $9.1 million.
- Meihua Intl Medical Techs (NASDAQ:MHUA) shares moved upwards by 6.38% to $0.31. The market value of their outstanding shares is at $8.0 million. As per the press release, FY earnings came out today.
Losers
- Inspire Veterinary (NASDAQ:IVP) stock decreased by 8.0% to $1.5 during Friday's after-market session. The company's market cap stands at $2.2 million.
- Madrigal Pharmaceuticals (NASDAQ:MDGL) shares declined by 6.78% to $305.0. The market value of their outstanding shares is at $6.7 billion.
- Shuttle Pharmaceuticals (NASDAQ:SHPH) stock decreased by 6.37% to $0.29. The market value of their outstanding shares is at $1.8 million.
- Verrica Pharmaceuticals (NASDAQ:VRCA) shares decreased by 6.3% to $0.46. The company's market cap stands at $42.9 million.
- Polyrizon (NASDAQ:PLRZ) shares decreased by 5.56% to $0.32. The market value of their outstanding shares is at $12.7 million.
- Petros Pharma (NASDAQ:PTPI) stock fell 5.01% to $0.05. The market value of their outstanding shares is at $1.2 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.